Tesofensine/metoprolol - Saniona

Drug Profile

Tesofensine/metoprolol - Saniona

Alternative Names: metoprolol/tesofensine; Tesomet

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Saniona
  • Class Antihyperglycaemics; Chlorobenzenes; Heterocyclic bicyclo compounds; Obesity therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Biogenic monoamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prader-Willi syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 06 Jan 2017 Saniona plans to apply for Orphan Drug status in Prader-Willi syndrome in USA and European Union (Saniona website, January 2017)
  • 03 Jan 2017 Efficacy data from a phase IIa trial in Type-2 diabetes released by Saniona
  • 22 Dec 2016 Phase-II clinical trials in Prader-Willi syndrome (In adolescents, In adults) in Hungary (PO) (EudraCT2016-003694-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top